ADC Therapeutics SA (ADCT) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ProQR Therapeutics N.V. (PRQR) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 33.5% versus a loss of 65.0%. Over five years, PRQR leads with a -80.1% price change compared with -93.8% for ADCT. ProQR Therapeutics N.V. is the larger company by market cap ($225.1 million vs $222.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | PRQR |
|---|---|---|
| Share price | $1.74 | $1.60 |
| Market cap | $222.14M | $225.08M |
| 1-day change | +9.43% | +1.59% |
| YTD return | -54.96% | -22.28% |
| 1-year return | -64.98% | -33.47% |
| 5-year return | -93.76% | -80.08% |
| EPS (TTM) | $-0.60 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $3.10 |
| 52-week low | $0.78 | $1.33 |
| Distance from 52-week high | -65.06% | -48.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +91.38% | +387.77% |
| Average volume | 1.43M | 796.41K |
| Shares outstanding | 127.67M | 141.12M |
| Employees | 188 | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRQR has outperformed ADCT by 31.5 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
ADCT vs PRQR FAQ
Which is bigger, ADC Therapeutics SA or ProQR Therapeutics N.V.?
ProQR Therapeutics N.V. (PRQR) is larger, with a market capitalization of $225.08M compared with $222.14M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or PRQR?
PRQR returned -33.47% over the past 12 months, compared with -64.98% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and ProQR Therapeutics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.